Efficacy and tolerability of treatment with line II nilotinib in a patient with coronary artery disease

Elisa Roncoroni, Maria Luisa Pioltelli, Anna Maria Frustaci, Ester Pungolino, Enrica Morra

DOI: https://doi.org/10.7175/cmi.v7i1S.1142


The possible cardiotoxicity of tyrosine kinase inhibitors (TKIs) is a topic of extreme interest because in the clinical practice it is frequent the management of elderly patients, in which are common comorbidities and polypharmacotherapies. Several studies have been conducted to evaluate the cardiotoxicity intrinsic to TKIs, but the results are, however, often discordant between in vitro studies and clinical practice. We present a case report about a male patient with several numerous comorbidities: COPD, diabetes mellitus and coronary artery disease. After the failure of imatinib therapy, the patient has switched in second-line to nilotinib therapy, 400 mg twice a day. The therapy was discussed and arranged with the cardiologists, with strict monitoring of cardiac and metabolic parameters. The therapy with nilotinib has allowed to obtain an optimal response according to the ELN guidelines and, from the sixth month of treatment, a major molecular response was obtained. From the standpoint of cardiologists, the patient has maintained a good compensation, despite the permanence of anginal symptoms, which required repeated therapeutic adjustments. Our case shows that nilotinib may be a well tolerated and effective therapy in a patient suffering from a major heart disease, maintaining a close clinical and cardiologic monitoring.


Nilotinib; Cardiotoxicity; Coronary artery disease Keywords: Nilotinib; Cardiotoxicity; Coronary artery disease

Full Text



Abstract: 335 views
HTML: 1030 views
PDF: 228 views


  • There are currently no refbacks.

© SEEd srl